Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial) (NCT02756793)
Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial): A Randomized Phase II Trial
🩺 Plain-English Summary (8th-Grade Level)
A multicenter randomized phase II trial of stereotactic body radiotherapy for oligo-progressive metastatic cancers. Eligible patients will be randomized in a 1:2 ratio between receiving their standard of care therapy or stereotactic ablative radiotherapy (SABR) to all sites of oligo-progressive lesions.Radiotherapy will be administered as soon as possible following randomization, and subjects will be followed until next disease progression. The primary outcome is progression-free survival (PFS).
Who can join: Review the eligibility criteria below.
Location: Alberta Health Services-Cross Cancer Institute — Edmonton, Alberta
Age range: 18 Years
🧪 Interventions in This Study
- Stereotactic Ablative Radiotherapy (SABR) (RADIATION)
- Standard of Care Treatment (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- Alberta Health Services-Cross Cancer Institute — Edmonton, Alberta
- BC Cancer - Prince George — Prince George, British Columbia
- BC Cancer Fraser Valley Centre — Surrey, British Columbia
- BC Cancer Agency Branch — Vancouver, British Columbia
- BC Cancer - Victoria Centre — Victoria, British Columbia
- London Regional Cancer Program — London, Ontario
- Princess Margaret Cancer Centre — Toronto, Ontario
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Cancer
- A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors — Hartford, Connecticut
- Niraparib in Tumors Metastatic to the CNS — Boston, Massachusetts
- A Study of Stereotactic Body Radiotherapy (SBRT) and Surgical Stabilization for People With Cancer That Has Spread to the Bone — Basking Ridge, New Jersey
- An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer — New York, New York
- CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer — Boston, Massachusetts
Explore by condition: All Metastatic Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.